A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Exclusion Criteria

• •1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing.
• •2. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.
• •3. Thymectomy performed \< 12 months prior to screening.
• •4. Total IgG level \<6 g/L (at screening).
• •5. Absolute neutrophil count \<1500 cells/mm3(at screening).